Testing spinal cord stimulation and arm exercises for multiple sclerosis
Tests a non-invasive spinal stimulation device with arm exercises in adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Pilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple sclerosis who have weak arm and hand function. It tests spinal cord stimulation with the SCONE device together with arm exercises.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Multiple sclerosis (by the revised McDonald criteria) with arm and hand problems. 9-Hole Peg Test score at least 20% slower than normal values. EDSS score between 3.0 and 6.5.
- Earlier treatment
- Disease-modifying treatment that has been stable for at least 6 months before joining.
Main reasons for not taking part
- Relapse or corticosteroid treatment in the last 3 months
- Severe arm spasticity (Modified Ashworth Scale above 3)
- Implanted electrical device such as a pacemaker or spinal cord stimulator
- Epilepsy or uncontrolled seizures
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07152145, who can take part
Where in Spain
- Hospital del MarBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Parc de Salut Mar
- Trial code
- NCT07152145
- Record updated
- 3 September 2025
- Original description
The goal of this clinical trial is to evaluate whether non-invasive spinal cord neuromodulation with the SCONE™ device can improve upper limb function in people with multiple sclerosis. The study will investigate if combining SCONE™ therapy with rehabilitation exercises leads to improvements in arm and hand movement, and whether the therapy is safe and well tolerated in this patient population. Participants will receive non-invasive spinal cord stimulation with the SCONE™ device and perform rehabilitation exercises specifically focused on the upper limb.Read full original descriptionShow less
Transcutaneous Electrical Spinal Stimulation (tSCS) for Improving Upper Limb Function in People With MS
The goal of this clinical trial is to evaluate whether non-invasive spinal cord neuromodulation with the SCONE™ device can improve upper limb function in people with multiple sclerosis. The study will investigate if combining SCONE™ therapy with rehabilitation exercises leads to improvements in arm and hand movement, and whether the therapy is safe and well tolerated in this patient population. Participants will receive non-invasive spinal cord stimulation with the SCONE™ device and perform rehabilitation exercises specifically focused on the upper limb.
Inclusion: Age between 18 and 70 years; Diagnosis of Multiple Sclerosis (according to revised McDonald criteria); Upper limb dysfunction (9-Hole Peg Test score ≥ 20% slower than normative values); Stable disease-modifying treatment for ≥ 6 months before enrollment; Expanded Disability Status Scale (EDSS) score between 3.0 and 6.5; Ability to provide informed consent.
Exclusion: Relapse or corticosteroid treatment within the last 3 months; Epilepsy or uncontrolled seizures; Severe psychiatric disorders or cognitive impairment interfering with study procedures; Severe spasticity of the upper limb (Modified Ashworth Scale > 3); Implanted electrical devices (pacemaker, spinal cord stimulator); Pregnant or breastfeeding women; Participation in another interventional clinical trial within the last 3 months.